Navigation Links
Oramed Pharmaceuticals Announces Reverse Stock Split

JERUSALEM, January 22, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCQB:ORMP) (, a developer of oral drug delivery systems, announced today that its previously announced one for twelve reverse stock split has become effective. As of the open of business on January 23, 2013, the shares of Oramed will be trading on a reverse split-adjusted basis on the OTCQB Market under the symbol "ORMPD," which replaces the previous symbol "ORMP" for the next 20 business days. Oramed effected the reverse stock split in order to help it meet the qualifications for listing its shares on the Nasdaq Capital Market.  

The reverse split reduces the number of shares of Oramed's authorized shares of common stock from approximately 200,000,000 to approximately 16,666,667 and outstanding shares common stock from approximately 86,505,020 to approximately 7,209,652. The exercise price and the number of shares of common stock issuable under Oramed's outstanding warrants and options have been proportionately adjusted to reflect the reverse stock split. Fractional shares created as a result of the stock split will be rounded up to the next whole share.

 "We are taking steps to move our company forward on many fronts and this reverse stock split puts us closer to our goal of up-listing to a major market in the U.S.," commented Oramed CEO, Nadav Kidron .

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching FDA-approved Phase 2 clinical trials, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 1b/2a trials. The company's corporate and R&D headquarters are based in Jerusalem.  

The company's fact sheet can be viewed here.

For more information, the content of which is not part of this press release, please visit

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss how the reverse stock split puts us closer to our goal of up-listing to a major market in the U.S. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to difficulties or delays in obtaining approval for the listing of our shares on  Nasdaq, Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001       

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
2. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
3. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
4. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
5. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
6. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
7. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
8. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
11. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
Post Your Comments:
(Date:12/1/2015)... Dr. Harry Lander , President of Regen, ... Chief Science Officer and recruits five distinguished scientists ... , President of Regen, expands his role to include ... five distinguished scientists to join advisory team --> ... to include serving as Chief Science Officer ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced that its scientific team is in the ... cells. The announcement starts a new phase toward launching the simple, quick system for ... lipoaspirate obtained from liposuction of excess adipose tissue. , Lipoaspirate, contains a large ...
(Date:11/30/2015)... Partnership includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ... up through cost cuts of priority ... licensees based anywhere in the world will have the right to make, use and ... , where licensees based anywhere in the world will have the right to make, ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 at Melbourne ... on a worldwide tour including several North American tour dates. The Exhibition is ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):